Page last updated: 2024-09-05

erlotinib hydrochloride and poziotinib

erlotinib hydrochloride has been researched along with poziotinib in 2 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (poziotinib)	Trials (poziotinib)	Recent Studies (post-2010) (poziotinib)
4,353	786	3,033	51	12	51

Protein Interaction Comparison

Protein	Taxonomy	erlotinib hydrochloride (IC50)	poziotinib (IC50)
Epidermal growth factor receptor	Homo sapiens (human)		0.002
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)		0.0086

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Cha, MY; Chae, YJ; Kim, M; Kim, MS; Kim, YH; Lee, GS; Lee, KH; Lee, KO; Park, J; Park, SB; Song, JY; Suh, KH	1
Kaul, SC; Kumar, V; Malik, V; Sundar, D; Wadhwa, R	1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and poziotinib

Article	Year
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. International journal of cancer, 2012, May-15, Volume: 130, Issue:10 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays	2012
Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers. Biomolecules, 2021, 01-26, Volume: 11, Issue:2 Topics: Adenosine Triphosphate; Antineoplastic Agents; Caffeic Acids; Computational Biology; Computer Simulation; Dimerization; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Phenylethyl Alcohol; Quinazolines; Withanolides	2021

Article

Year

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.

International journal of cancer, 2012, May-15, Volume: 130, Issue:10

Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays

2012

Computational Insights into the Potential of Withaferin-A, Withanone and Caffeic Acid Phenethyl Ester for Treatment of Aberrant-EGFR Driven Lung Cancers.

Biomolecules, 2021, 01-26, Volume: 11, Issue:2

Topics: Adenosine Triphosphate; Antineoplastic Agents; Caffeic Acids; Computational Biology; Computer Simulation; Dimerization; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Phenylethyl Alcohol; Quinazolines; Withanolides

2021